Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
MULTICENTER STUDY
Carlos M Campos, Roxana Mehran, Davide Capodanno, Ruth Owen, Stephan Windecker, Olivier Varenne, Gregg W Stone, Marco Valgimigli, Ludhmila Abrahão Hajjar, Roberto Kalil Filho, Keith Oldroyd, Marie-Claude Morice, Philip Urban, Alexandre Abizaid
BACKGROUND: Oncological patients with coronary artery disease face an elevated risk of hemorrhagic and ischemic events following percutaneous coronary intervention. Despite medical guidelines recommending minimal dual antiplatelet therapy (DAPT) duration for patients with cancer, dedicated data on abbreviated DAPT in this population is lacking. This study aims to evaluate the occurrence of ischemic and hemorrhagic events in patients with cancer compared with other high-bleeding risk individuals...
April 2024: Circulation. Cardiovascular Interventions
#2
MULTICENTER STUDY
Marianna Adamo, Giulio Russo, Matteo Pagnesi, Edoardo Pancaldi, Hannes Alessandrini, Martin Andreas, Luigi P Badano, Daniel Braun, Kim A Connelly, Paolo Denti, Rodrigo Estevez-Loureiro, Neil Fam, Mara Gavazzoni, Rebecca T Hahn, Claudia Harr, Joerg Hausleiter, Dominique Himbert, Daniel Kalbacher, Edwin Ho, Azeem Latib, Edith Lubos, Sebastian Ludwig, Laura Lupi, Philipp Lurz, Vanessa Monivas, Georg Nickenig, Daniela Pedicino, Giovanni Pedrazzini, Alberto Pozzoli, Denise Pires Marafon, Roberta Pastorino, Fabien Praz, Joseph Rodes-Cabau, Christian Besler, Anne Rebecca Schöber, Joachim Schofer, Andrea Scotti, Kerstin Piayda, Horst Sievert, Gilbert H L Tang, Alessandro Sticchi, David Messika-Zeitoun, Holger Thiele, Florian Schlotter, Ralph Stephan von Bardeleben, John Webb, Julien Dreyfus, Stephan Windecker, Martin Leon, Francesco Maisano, Marco Metra, Maurizio Taramasso
BACKGROUND: Data on the prognostic role of the TRI-SCORE in patients undergoing transcatheter tricuspid valve intervention (TTVI) are limited. OBJECTIVES: The aim of this study was to evaluate the performance of the TRI-SCORE in predicting outcomes of patients undergoing TTVI. METHODS: TriValve (Transcatheter Tricuspid Valve Therapies) is a large multicenter multinational registry including patients undergoing TTVI. The TRI-SCORE is a risk model recently proposed to predict in-hospital mortality after tricuspid valve surgery...
April 8, 2024: JACC. Cardiovascular Interventions
#3
JOURNAL ARTICLE
Caglayan Demirel, Christoph Fritz Rothenbühler, Markus Huber, Michelle Schweizer, Inga Todorski, David Alexander Gloor, Stephan Windecker, Jonas Lanz, Stefan Stortecky, Thomas Pilgrim, Gabor Erdoes
Background: Transcatheter aortic valve replacement (TAVR) is a treatment option for severe aortic valve stenosis. Pre-TAVR assessments, extending beyond anatomy, include evaluating frailty. Potential frailty parameters in pre-TAVR computed tomography (CT) scans are not fully explored but could contribute to a comprehensive frailty assessment. The primary objective was to investigate the impact of total muscle area (TMA) and visceral adipose tissue (VAT) as frailty parameters on 5-year all-cause mortality in patients undergoing TAVR...
February 26, 2024: Journal of Clinical Medicine
#4
JOURNAL ARTICLE
Kendra J Grubb, John C Lisko, Daniel O'Hair, William Merhi, John K Forrest, Paul Mahoney, Nicolas M Van Mieghem, Stephan Windecker, Steven J Yakubov, Mathew R Williams, Stanley J Chetcuti, G Michael Deeb, Neal S Kleiman, Andrew D Althouse, Michael J Reardon
BACKGROUND: Data on valve reintervention after transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR) are limited. OBJECTIVES: The authors compared the 5-year incidence of valve reintervention after self-expanding CoreValve/Evolut TAVR vs SAVR. METHODS: Pooled data from CoreValve and Evolut R/PRO (Medtronic) randomized trials and single-arm studies encompassed 5,925 TAVR (4,478 CoreValve and 1,447 Evolut R/PRO) and 1,832 SAVR patients...
March 7, 2024: JACC. Cardiovascular Interventions
#5
JOURNAL ARTICLE
Karl-Philipp Rommel, Guillaume Bonnet, Vera Fortmeier, Lukas Stolz, Anne R Schöber, Jennifer von Stein, Mohammad Kassar, Muhammed Gerçek, Sebastian Rosch, Thomas J Stocker, Maria I Körber, Karl-Patrik Kresoja, Tanja K Rudolph, Roman Pfister, Stephan Baldus, Stephan Windecker, Holger Thiele, Fabien Praz, Jörg Hausleiter, Volker Rudolph, Daniel Burkhoff, Philipp Lurz
AIMS: While invasively determined congestion holds mechanistic and prognostic significance in acute heart failure (HF), its role in patients with tricuspid regurgitation (TR)-related right- heart failure (HF) undergoing transcatheter tricuspid valve intervention (TTVI) is less well established. A comprehensive understanding of congestion patterns might aid in procedural planning, risk stratification, and the identification of patients who may benefit from adjunctive therapies before undergoing TTVI...
April 4, 2024: European Journal of Heart Failure
#6
JOURNAL ARTICLE
Emrush Rexhaj, Sarah Bär, Rodrigo Soria, Yasushi Ueki, Jonas D Häner, Tatsuhiko Otsuka, Raminta Kavaliauskaite, George Cm Siontis, Stefan Stortecky, Hiroki Shibutani, David Spirk, Thomas Engstrøm, Irene Lang, Laura Morf, Maria Ambühl, Stephan Windecker, Sylvain Losdat, Konstantinos C Koskinas, Lorenz Räber
BACKGROUND AND AIMS: The effects of protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on endothelial function as assessed by flow-mediated dilation (FMD) in patients with acute myocardial infarction (AMI) are unknown. Therefore, we aimed to investigate the effects of the PCSK9 inhibitor alirocumab added to high-intensity statin on FMD, and its association with coronary atherosclerosis in non-infarct related arteries using intracoronary intravascular ultrasound (IVUS), near-infrared spectroscopy (NIRS), and optical coherence tomography (OCT)...
March 6, 2024: Atherosclerosis
#7
JOURNAL ARTICLE
Marco Valgimigli, Felice Gragnano, Mattia Branca, Anna Franzone, Bruno R da Costa, Usman Baber, Takeshi Kimura, Yangsoo Jang, Joo-Yong Hahn, Qiang Zhao, Stephan Windecker, Charles M Gibson, Hirotoshi Watanabe, Byeong-Keuk Kim, Young Bin Song, Yunpeng Zhu, Pascal Vranckx, Shamir Mehta, Kenji Ando, Sung Jin Hong, Hyeon-Cheol Gwon, Patrick W Serruys, George D Dangas, Eùgene P McFadden, Dominick J Angiolillo, Dik Heg, Paolo Calabrò, Peter Jüni, Roxana Mehran
IMPORTANCE: Among patients undergoing percutaneous coronary intervention (PCI), it remains unclear whether the treatment efficacy of P2Y12 inhibitor monotherapy after a short course of dual antiplatelet therapy (DAPT) depends on the type of P2Y12 inhibitor. OBJECTIVE: To assess the risks and benefits of ticagrelor monotherapy or clopidogrel monotherapy compared with standard DAPT after PCI. DATA SOURCES: MEDLINE, Embase, TCTMD, and the European Society of Cardiology website were searched from inception to September 10, 2023, without language restriction...
March 20, 2024: JAMA Cardiology
#8
JOURNAL ARTICLE
Benedikt Bernhard, Jonathan Schütze, Zoe L Leib, Giancarlo Spano, Martina Boscolo Berto, Adam Bakula, Daijiro Tomii, Isaac Shiri, Nicolas Brugger, Stefano De Marchi, David Reineke, Stephan Dobner, Dik Heg, Fabien Praz, Jonas Lanz, Stefan Stortecky, Thomas Pilgrim, Stephan Windecker, Christoph Gräni
PURPOSE: Our study aimed to determine whether 4D cardiac computed tomography (4DCCT) based quantitative myocardial analysis may improve risk stratification and can predict reverse remodeling (RRM) and mortality after transcatheter aortic valve implantation (TAVI). METHODS: Consecutive patients undergoing clinically indicated 4DCCT prior to TAVI were prospectively enrolled. 4DCCT-derived left- (LV) and right ventricular (RV), and left atrial (LA) dimensions, mass, ejection fraction (EF) and myocardial strain were evaluated to predict RRM and survival...
March 13, 2024: European Journal of Radiology
#9
JOURNAL ARTICLE
Raghava S Velagaleti, Camden Harrell, Justin Michalski, Thierry Lefèvre, Stephan Windecker, Ton Slagboom, Shigeru Saito, Jacques Koolen, Ron Waksman, David E Kandzari
BACKGROUND: Percutaneous coronary intervention (PCI) is considered less safe in patients with reduced ejection fraction (EF), an impression based on older data. Whether the safety and durability of contemporary PCI are different in patients with reduced EF compared with normal EF patients is unknown. METHODS: Patients from the BIOFLOW II, IV and V clinical trials were grouped as normal EF (≥50%) and reduced EF (30%-50%). Using multivariable logistic regression and cox proportional hazards regression, we determined relations of EF category with procedural safety (a composite of cardiac death, myocardial infarction, stroke and urgent coronary artery bypass grafting within 30 days of PCI) and target lesion failure (TLF; comprising cardiac death, target vessel myocardial infarction, target vessel revascularization within 1 year of PCI) respectively...
March 5, 2024: Catheterization and Cardiovascular Interventions
#10
JOURNAL ARTICLE
Giulio Russo, Rebecca T Hahn, Hannes Alessandrini, Martin Andreas, Luigi P Badano, Daniel Braun, Kim A Connelly, Paolo Denti, Rodrigo Estevez-Loureiro, Neil Fam, Mara Gavazzoni, Joerg Hausleiter, Dominique Himbert, Daniel Kalbacher, Azeem Latib, Edith Lubos, Sebastian Ludwig, Philipp Lurz, Vanessa Monivas, Georg Nickenig, Daniela Pedicino, Giovanni Pedrazzini, Alberto Pozzoli, Fabien Praz, Joseph Rodes-Cabau, Karl-Philipp Rommel, Joachim Schofer, Horst Sievert, Gilbert Tang, Holger Thiele, Matthias Unterhuber, Ralph Stephan von Bardeleben, John Webb, Stephan Windecker, Martin Leon, Francesco Maisano, Maurizio Taramasso
AIMS: T-TEER is an effective therapy for the treatment of tricuspid regurgitation (TR). However, the effects of leaflets clipping on tricuspid valve annulus (TA) have not been investigated in detail. The aim of this study is to investigate the effects of tricuspid transcatheter edge-to-edge repair (T-TEER) on TA diameter. METHODS AND RESULTS: The TriValve registry (Transcatheter Tricuspid Valve Therapies, NCT03416166) collected 556 patients from 22 European and North American centres undergoing transcatheter tricuspid valve interventions from 2016 to 2022...
March 2, 2024: International Journal of Cardiology
#11
JOURNAL ARTICLE
Joanna Bartkowiak, Hari Vivekanantham, Mohammad Kassar, Chrisoula Dernektsi, Vratika Agarwal, Mark Lebehn, Stephan Windecker, Nicolas Brugger, Rebecca T Hahn, Fabien Praz
AIM: To identify anatomical computed tomography (CT) predictors of procedural and clinical outcomes in patients undergoing tricuspid transcatheter edge-to-edge repair (T-TEER). METHODS AND RESULTS: Consecutive patients undergoing T-TEER between March 2018 to December 2022 who had cardiac CT prior to the procedure were included. CT scans were automatically analyzed using a dedicated software that employs deep learning techniques to provide precise anatomical measurements and volumetric calculations...
February 20, 2024: Journal of Cardiovascular Computed Tomography
#12
EDITORIAL
Stephan Windecker, Jonas Dominik Häner
No abstract text is available yet for this article.
January 2024: Praxis
#13
JOURNAL ARTICLE
Stephan Windecker, Martine Gilard, Stephan Achenbach, Alain Cribier, Victoria Delgado, Nataliya Deych, Inga Drossart, Hélène Eltchaninoff, Alan G Fraser, Alexandra Goncalves, Gerhard Hindricks, Richard Holborow, Arie Pieter Kappetein, John Kilmartin, Jana Kurucova, Thomas F Lüscher, Roxana Mehran, Donal B O'Connor, Mark Perkins, Eigil Samset, Ralph Stephan von Bardeleben, Franz Weidinger
Research performed in Europe has driven cardiovascular device innovation. This includes, but is not limited to, percutaneous coronary intervention, cardiac imaging, transcatheter heart valve implantation, and device therapy of cardiac arrhythmias and heart failure. An important part of future medical progress involves the evolution of medical technology and the ongoing development of artificial intelligence and machine learning. There is a need to foster an environment conducive to medical technology development and validation so that Europe can continue to play a major role in device innovation while providing high standards of safety...
February 16, 2024: European Heart Journal
#14
JOURNAL ARTICLE
Bashir Alaour, Enrico Ferrari, Dik Heg, David Tueller, Thomas Pilgrim, Olivier Muller, Stephane Noble, Raban Jeger, Oliver Reuthebuch, Stefan Toggweiler, Christian Templin, Peter Wenaweser, Fabian Nietlispach, Maurizio Taramasso, Christoph Huber, Marco Roffi, Stephan Windecker, Stefan Stortecky
BACKGROUND: Studies comparing long-term outcomes between non-vitamin K antagonist (VKA) oral anticoagulant agents (direct oral anticoagulant agents [DOACs]) and VKA anticoagulant agents after transcatheter aortic valve replacement (TAVR) are scarce, with conflicting results. OBJECTIVES: The aim of this study was to examine the periprocedural, short-term, and long-term safety and effectiveness of DOACs vs VKAs in patients undergoing TAVR via femoral access with concomitant indications for oral anticoagulation...
February 12, 2024: JACC. Cardiovascular Interventions
#15
JOURNAL ARTICLE
Uwe Zeymer, Tobias Heer, Taoufik Ouarrak, Ibrahim Akin, Marko Noc, Janina Stepinska, Keith Oldroyd, Pranas Serpytis, Giles Montalescot, Kurt Huber, Stephan Windecker, Stefano Savonitto, Christiaan Vrints, Steffen Schneider, Steffen Desch, Holger Thiele
BACKGROUND: We analysed consecutive patients with acute myocardial infarction complicated by cardiogenic shock (CS) who were enrolled into the CULPRIT-SHOCK randomized controlled trial (RCT) and those with exclusion criteria who were included into the accompanying registry. METHODS: In total, 1,075 patients with infarct-related CS were screened for CULPRIT-SHOCK in 83 specialised centres in Europe; 369 of them had exclusion criteria for the RCT and were enrolled into the registry...
February 13, 2024: European Heart Journal. Acute Cardiovascular Care
#16
JOURNAL ARTICLE
Yukio Ozaki, Sung-Jin Hong, Dik Heg, Enrico Frigoli, Pascal Vranckx, Marie-Claude Morice, Bernard Chevalier, Yoshinobu Onuma, Stephan Windecker, Maurizio Di Biasi, Robert Whitbourn, Dariusz Dudek, Owen Christopher Raffel, Kiyokazu Shimizu, Paolo Calabrò, Ole Fröbert, Fernando Cura, Jurrien Ten Berg, Pieter C Smits, Marco Valgimigli
No abstract text is available yet for this article.
February 1, 2024: Canadian Journal of Cardiology
#17
JOURNAL ARTICLE
Andreas Leha, Cynthia Huber, Tim Friede, Timm Bauer, Andreas Beckmann, Raffi Bekeredjian, Sabine Bleiziffer, Eva Herrmann, Helge Möllmann, Thomas Walther, Friedhelm Beyersdorf, Christian Hamm, Arnaud Künzi, Stephan Windecker, Stefan Stortecky, Ingo Kutschka, Gerd Hasenfuß, Stephan Ensminger, Christian Frerker, Tim Seidler
No abstract text is available yet for this article.
January 2024: European heart journal. Digital health
#18
JOURNAL ARTICLE
Miklos Rohla, Shirley Xinyu Ye, Hiroki Shibutani, Jolie Bruno, Tatsuhiko Otsuka, Jonas D Häner, Sarah Bär, Fabrice Temperli, Raminta Kavaliauskaite, Jonas Lanz, Stefan Stortecky, Fabien Praz, Lukas Hunziker, Thomas Pilgrim, George Cm Siontis, Sylvain Losdat, Stephan Windecker, Lorenz Räber
BACKGROUND: Evidence to support immediate P2Y12 inhibitor loading in ST-segment elevation myocardial infarction (STEMI) is limited. OBJECTIVES: This study sought to compare outcomes of STEMI patients receiving immediate or delayed P2Y12 inhibitor treatment. METHODS: Using data from the prospective Bern-PCI registry between 2016 and 2020, we stratified STEMI patients undergoing percutaneous coronary intervention according to time periods with different institutional recommendations regarding P2Y12 inhibitor pretreatment...
January 8, 2024: JACC. Cardiovascular Interventions
#19
JOURNAL ARTICLE
Gennaro Sardella, Alessandro Spirito, Samantha Sartori, Dominick J Angiolillo, Pascal Vranckx, Jose M De la Torre Hernandez, Mitchell W Krucoff, Sripal Bangalore, Deepak L Bhatt, Gianluca Campo, Davide Cao, Bassem M Chehab, James W Choi, Yihan Feng, Junbo Ge, Katherine Godfrey, James Hermiller, Vijay Kunadian, Raj R Makkar, Aziz Maksoud, Franz-Josef Neumann, Hector Picon, Shigeru Saito, Holger Thiele, Ralph Toelg, Olivier Varenne, Birgit Vogel, Yujie Zhou, Marco Valgimigli, Stephan Windecker, Roxana Mehran
This analysis aimed to evaluate the effect of 1- versus 3-month dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in older patients. Data from three prospective, single-arm studies (XIENCE Short DAPT Program), including high bleeding risk (HBR) patients successfully treated with an everolimus-eluting stent (XIENCE, Abbott) were analyzed. DAPT was discontinued at 1 or at 3 months in patients free from ischemic events and adherent to DAPT. Patients were stratified according to age (≥75 and <75 years)...
January 5, 2024: American Journal of Cardiology
#20
JOURNAL ARTICLE
Antonio Landi, Victor Aboyans, Dominick J Angiolillo, Dan Atar, Davide Capodanno, Keith A A Fox, Sigrun Halvorsen, Stefan James, Peter Jüni, Sergio Leonardi, Roxana Mehran, Gilles Montalescot, Eliano Pio Navarese, Josef Niebauer, Angelo Oliva, Raffaele Piccolo, Susanna Price, Robert F Storey, Heinz Völler, Pascal Vranckx, Stephan Windecker, Marco Valgimigli
Antithrombotic therapy represents the cornerstone of the pharmacological treatment in patients with acute coronary syndrome (ACS). The optimal combination and duration of antithrombotic therapy is still matter of debate requiring a critical assessment of patient comorbidities, clinical presentation, revascularization modality, and/or optimization of medical treatment. The 2023 European Society of Cardiology (ESC) guidelines for the management of patients with ACS encompassing both patients with and without ST segment elevation ACS have been recently published...
February 9, 2024: European Heart Journal. Acute Cardiovascular Care
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
